RASSF1 and breast carcinoma: In contrast, resveratrol (5 or 50 mg) administered twice daily for 12 weeks to 39 women (median age of 59.5 years in the 5 mg group versus a median age of 54 years in the 50 mg group) with increased breast cancer risk displayed chemopreventative properties by inducing RASSF-1α demethylation and re-expression [211].